Magdalena Leszczyniecka PhD, MBA

Dr. Magdalena Leszczyniecka is a President and CEO of STC Biologics, Inc a biotechnology company focusing on biosimilar development. STC Biologics was founded in 2009 with the goal to increase drug access to those who can’t afford branded drugs. STC Biologics is a drug development company focusing on biosimilar development specializing in process development, analytics and regulatory submissions from clone to Phase I clinical studies. STC Biologics’ business model is to partner its assets post Phase I studies with various commercial partners across the globe. STC Biologics’ first biosimilar antibody, STC101 is currently entering Phase I clinical trial under EMA guidance. There are two other products currently in development. Magdalena brings over 15 years of experience in oncology, and 12 years of experience in drug development. Before STC Biologics, Inc., she worked in two venture capital firms, Flagship Ventures and Atlas Venture, where she assisted creation of new start-ups in the MA area. Prior to her work in venture capital, she lead the development of MM-121, an anti-ErbB3 antibody that was recently partnered with Sanofi-Aventis at Merrimack Pharmaceuticals. She started her career at Novartis Pharmaceuticals back in 2002. She received her PhD from a joined program between Columbia University and NYU and MBA from Babson College.